GlassScriptPhysician profile
Dhiraj Bedi
NPI 1225130198
$10,811.37
in general payments reported to CMS, 2019-2025
44 companies · $5,483 in 2025
The $5,483 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $690 · 2021: $1,080 · 2022: $935 · 2023: $818 · 2024: $1,058 · 2025: $5,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,329 · Food and Beverage: $3,001 · Education: $27.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,329.14 |
| Food and Beverage | $3,001.23 |
| Education | $27.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,231.56 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $855.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $518.70 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $478.69 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $356.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $289.12 | 2019-2025 | |
| Glaxosmithkline, LLC. | $215.27 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $204.34 | 2019-2023 | |
| Vanda Pharmaceuticals INC. | $202.97 | 2022-2023 | Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $195.71 | 2020-2025 | Eohilia, Trintellix |
| Janssen Pharmaceuticals, INC | $193.40 | 2019-2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $191.33 | 2020-2025 | Livalo, Seglentis, Zoryve |
| Biohaven Pharmaceuticals, INC. | $189.76 | 2021 | |
| Exact Sciences Corporation | $171.15 | 2024-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $159.85 | 2022-2025 | Rexulti |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhiraj Bedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.